Physician profile
Martha Lloyd
NPI 1669660965
$9,315.88
in general payments reported to CMS, 2019-2025
44 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $1,118 · 2021: $1,336 · 2022: $1,096 · 2023: $1,300 · 2024: $1,603 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.93 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,470.86 | 2021-2025 | |
| Novo Nordisk INC | $1,357.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,094.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $878.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $793.66 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $439.41 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.05 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $369.76 | 2022-2025 | |
| Pfizer INC. | $359.24 | 2019-2025 | |
| Amgen INC. | $208.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $160.74 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $158.46 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $124.04 | 2019-2022 | |
| Ibsa Pharma INC. | $114.73 | 2021-2025 | Tirosint, Licart, Tirosint |
| Supernus Pharmaceuticals, INC. | $114.37 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.